Medtronic plc MDT
Healthcare · Medical Devices · Ireland · S&P 500
68
Based on the available data, Medtronic plc gets an algorithmic score of 68/100. It trades at 87.09 $, with a bullish technical trend (RSI 39.8) and 23.8% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low beta (0.37): defensive profile.
- Meaningful dividend (3.31%).
Weaknesses
- —
Fundamentals
| P/E | 21.45 |
| Forward P/E | 13.59 |
| PEG | 1.60 |
| P/B | 2.22 |
| EV/EBITDA | 12.62 |
| P/S | 2.97 |
| ROE % | 10.65 |
| ROA % | 5.12 |
| Gross margin % | 65.27 |
| Operating margin % | 19.33 |
| Net margin % | 13.93 |
| Revenue growth % (y/y) | 13.70 |
| Earnings growth % (y/y) | 40.70 |
| Revenue CAGR % | 5.21 |
| Earnings CAGR % | 8.51 |
| Debt/Equity % | 55.37 |
| Current ratio | 2.07 |
| FCF yield % | 4.87 |
| Dividend yield % | 3.31 |
| Payout % | 70.20 |
Returns
| 1 month | -3.8 % |
| 3 months | +12.2 % |
| 6 months | +3.3 % |
| YTD | -7.0 % |
| 1 year | -4.5 % |
| 3 years | +19.7 % |
| 5 years | -19.7 % |
Risk
| 1-year volatility | 23.8 % |
| Beta | 0.37 |
| 5-year max drawdown | -43.5 % |
| Sharpe 1A | -0.24 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.